These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12779014

  • 21. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M, Porta C, De Amici M, Quaglini S, Cattabiani MA, Buzio C.
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [Abstract] [Full Text] [Related]

  • 22. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S, Ishikawa S, Yamauchi A, Saitou S.
    Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters.
    Boura P, Kountouras J, Lygidakis NJ, Safioleas M, Aphinives P.
    Hepatogastroenterology; 1999 Oct; 46(26):799-803. PubMed ID: 10370616
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma].
    Filippetti M, Torsello A, Cordiali Fei P, Bordignon V, Trento E, Tonachella R, Piperno G, Prignano G.
    Clin Ter; 2009 Oct; 160(2):139-43. PubMed ID: 19452104
    [Abstract] [Full Text] [Related]

  • 27. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch, Richter A, Lehmacher W, Jocham D.
    Folia Biol (Praha); 2003 Oct; 49(2):69-73. PubMed ID: 12779015
    [Abstract] [Full Text] [Related]

  • 28. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, Longo N, Perdonà S, Pignata S, Castello G, Scala S.
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [Abstract] [Full Text] [Related]

  • 29. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
    Ramsey S, Aitchison M, Graham J, McMillan DC.
    BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
    [Abstract] [Full Text] [Related]

  • 30. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE.
    Clin Cancer Res; 2006 Oct 01; 12(19):5850-8. PubMed ID: 17020993
    [Abstract] [Full Text] [Related]

  • 31. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
    Börgermann J, Friedrich I, Scheubel R, Kuss O, Lendemans S, Silber RE, Kreuzfelder E, Flohé S.
    Thorac Cardiovasc Surg; 2007 Feb 01; 55(1):24-31. PubMed ID: 17285470
    [Abstract] [Full Text] [Related]

  • 32. Effect of 2 anesthetic techniques on the postoperative proinflammatory and anti-inflammatory cytokine response and cellular immune function to minor surgery.
    Schneemilch CE, Ittenson A, Ansorge S, Hachenberg T, Bank U.
    J Clin Anesth; 2005 Nov 01; 17(7):517-27. PubMed ID: 16297751
    [Abstract] [Full Text] [Related]

  • 33. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun 01; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 34. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P, Mengo S, Mandalà M, Mauri E, Brivio F, Rovelli F, Confalonieri G, Longarini R, Bonfante A, Folli D, Meregalli S, Barni S, Tancini G, Giani L.
    J Biol Regul Homeost Agents; 1998 Jun 01; 12(1-2):38-41. PubMed ID: 9677534
    [Abstract] [Full Text] [Related]

  • 35. Changes in the levels of serum-soluble interleukin-2 receptor after surgical stress.
    Murakami S, Sakata H, Tsuji Y, Okubo K, Takahashi T, Kikuchi M, Hirayama R.
    Surg Today; 2003 Jun 01; 33(8):565-70. PubMed ID: 12884092
    [Abstract] [Full Text] [Related]

  • 36. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report.
    Tokunaga M, Masuda A, Mukai M, Nakamura H, Iwaki K, Terachi T.
    Tokai J Exp Clin Med; 2005 Jul 01; 30(2):111-5. PubMed ID: 16146201
    [Abstract] [Full Text] [Related]

  • 37. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
    Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H.
    Eur Cytokine Netw; 1999 Mar 01; 10(1):37-42. PubMed ID: 10210771
    [Abstract] [Full Text] [Related]

  • 38. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
    Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA.
    Cancer Res; 1987 Apr 15; 47(8):2188-95. PubMed ID: 3030546
    [Abstract] [Full Text] [Related]

  • 39. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J.
    Cancer; 2004 Dec 01; 101(11):2557-66. PubMed ID: 15517589
    [Abstract] [Full Text] [Related]

  • 40. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F, Fumagalli L, Chiarelli M, Denova M, Bertolini A, Cetta M, Nespoli A.
    Chir Ital; 2007 Dec 01; 59(5):635-40. PubMed ID: 18019635
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.